Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Should Growth Investors Buy This Little-Known Stock?
06:30am, Saturday, 24'th Sep 2022
Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
05:00pm, Thursday, 01'st Sep 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate
3 Cathie Wood Stocks for the Future
03:13pm, Sunday, 14'th Aug 2022 The Motley Fool
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
3 Cathie Wood Stocks for the Future
11:13am, Sunday, 14'th Aug 2022
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
09:55pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Veracyte (VCYT) delivered earnings and revenue surprises of 38.10% and 8.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2022 Results - Earnings Call Transcript
09:21pm, Tuesday, 02'nd Aug 2022
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebe
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
07:36pm, Tuesday, 02'nd Aug 2022
Veracyte (VCYT) delivered earnings and revenue surprises of 38.10% and 8.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons to Buy This Sizzling Growth Stock
03:23pm, Friday, 22'nd Jul 2022 The Motley Fool
Veracyte appears to be an intriguing pick for growth investors to compound their wealth over the long run.
3 Reasons to Buy This Sizzling Growth Stock
11:23am, Friday, 22'nd Jul 2022
Veracyte appears to be an intriguing pick for growth investors to compound their wealth over the long run.
Veracyte: Fading The Rally
03:58pm, Friday, 15'th Jul 2022
Shares of cancer diagnostics concern Veracyte, Inc. have shot up approximately 60% over the past month, snapping a deep decline. That said, valuations were stratospheric (22.6x FY21 sales at their pea
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
04:30pm, Thursday, 14'th Jul 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday,
Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should Know
01:55pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the posit
Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should Know
11:38am, Tuesday, 05'th Jul 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 41.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the posit
Veracyte to Present at Upcoming Investor Conferences
08:15am, Thursday, 26'th May 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate
Veracyte: Not A Healthy Diagnosis
09:51am, Thursday, 12'th May 2022
Veracyte has seen a real share price reversal over the past year. The company has been a momentum name, but not necessarily a pandemic beneficiary.
